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Abstract
Positron emission tomography (PET) is valuable for detecting locoregional 
recurrences of nasopharyngeal carcinoma (NPC) with a high sensitivity 
and fair specificity. A negative PET result is generally thought to confidently 
exclude the presence of a tumor. However, a false-negative PET scan is 
more dangerous than false-positive results because an undiscovered 
recurrent tumor may eventually lead to the patient’s death without proper 
treatment. In this report, we describe a false-negative PET scan in a NPC 
patient with a recurrent tumor in the left cavernous sinus, presenting as a 
new onset of left 6th cranial nerve palsy 1 year after irradiation. The first 
magnetic resonance imaging (MRI) and PET scan failed to disclose any 
abnormalities. The second MRI performed 3 months after the first scans 
demonstrated a new abnormal lesion in the left cavernous sinus, which 
had resolved in the following MRI after re-irradiation. Therefore, clinical 
observation with suggestive symptoms is still important, even with negative 
imaging results. Close follow-up with a series of imaging studies must be 
performed when indicated. [Tzu Chi Med J 2009;21(4):327–330]
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1. Introduction
Nasopharyngeal carcinoma (NPC) is endemic in 
Southern China, Hong Kong, Singapore and Taiwan 
[1,2]. Because NPC is highly radiosensitive and chemo-
sensitive, concurrent chemoradiotherapy is currently 
the standard treatment for NPC with a high cure rate, 
especially during the early stage [3–6]. However, loco-
regional failures still occur after definitive treatment 
[3–6]. In clinical practice, local examinations of the 
nasopharynx and computed tomography (CT) scans or 
magnetic resonance imaging (MRI) are performed reg-
ularly to detect these locoregional recurrences. How-
ever, it is sometimes difficult to distinguish between 
a recurrent tumor and post-irradiated changes [7] in 
the CT scans and MRI. In recent years, positron emis-
sion tomography (PET) with 18-fluoro-2-deoxyglucose 
(18F-FDG) has been shown to be useful in the detection 
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of tumors by identifying regions of accelerated glu-
cose metabolism. It has been proven effective in 
detecting recurrent NPC at the primary site, with a 
very high sensitivity of 100% and fair specificity of 
64–100% [7–10]. However, PET scans still have some 
diagnostic problems, especially with false-positive 
results, which are not uncommon because post-
irradiated tissue effects may also result in high glu-
cose metabolism [7,11–13]. In contrast, false-negative 
PET scan results have been rarely reported [7]. In 
this report, we describe a case in which a PET scan 
failed to detect a recurrent NPC occurring in the cav-
ernous sinus, which presented as diplopia and was dis-
closed and confirmed later using the results of serial 
MRI examinations.
2. Case report
A 45-year-old man with NPC presenting as diplopia 
for 3 months with the initial stage of T4N2M0 came 
to our hospital in January 2003. He received a 
7-week course of concurrent chemoradiotherapy at 
a dosage of 7000 centi-Gray (cGy) to the nasophar-
ynx and 6000 cGy to the bilateral neck immediately 
after the diagnosis of NPC was confirmed. After com-
plete treatment, diplopia resolved and MRI showed 
that the nasopharyngeal tumor had vanished. How-
ever, 12 months after completion of his treatment, 
he complained of diplopia for 3 weeks, and pre-
sented with limitation of lateral movement of his left 
eye, which was similar to the initial symptom. The 
initial MRI did not show any abnormal signals in the 
nasopharynx, skull base or cavernous sinus (Fig. 1). 
At the same time, PET scan showed no 18F-FDG up-
take in the nasopharynx or in the left cavernous 
sinus (Fig. 2). However, diplopia did not improve dur-
ing the next 3 months of observation. Therefore, MRI 
was performed again. This time, it showed an obvi-
ous tumor in the left cavernous sinus near the left 
internal carotid artery (Fig. 3). Concurrent chemora-
diotherapy was administered again with a dosage of 
5000 cGy covering the cavernous sinus. Lateral move-
ment of the left eye and diplopia began to improve 
soon after the treatment. When MRI was repeated 
3 months after treatment, it demonstrated that the 
left cavernous sinus lesion had disappeared (Fig. 4).
Fig. 1 — Coronal view of T1-weighted magnetic resonance 
imaging with gadolinium enhancement, which was per-
formed when the patient had diplopia again. No signifi-
cant lesions in bilateral cavernous sinus or the skull base 
were observed.
Fig. 2 — Coronal view of an 18-fluoro-2-deoxyglucose 
positron emission tomography scan at the level of the 
cavernous sinus shows no significant uptake in the cav-
ernous sinus, skull base, or nasopharynx.
Fig. 3 — Coronal view of T1-weighted magnetic resonance 
imaging with gadolinium enhancement, which was per-
formed 3 months after the initial imaging, shows a tumor 
in the left cavernous sinus.
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3. Discussion
Although NPC is curable with a 5-year survival rate of 
50–90% after curative radiotherapy [6,14], locore-
gional recurrences, with rates of 10–30% [6], remain 
a problem. Locoregional failures usually lead to the 
patients’ death. However, early detection and prompt 
treatment of these recurrences still present a chance 
to attain successful salvage. In the clinical practice, 
local mirror examination or direct endoscopic obser-
vation of the nasopharynx is performed regularly to 
detect recurrent tumors in the nasopharynx, and it is 
not difficult to take a biopsy of the nasopharyngeal 
lesion for pathological diagnosis. However, physical 
examinations cannot be used to detect recurrent 
NPC occurring in the base of the skull or the intracra-
nial space such as the cavernous sinus. Therefore, a 
CT scan or MRI is usually arranged for the patients 
having suggestive symptoms or signs of recurrent tu-
mors in the regions mentioned above [15,16]. How-
ever, these morphological imaging studies sometimes 
cannot be used to distinguish between the recurrent 
tumor and post-irradiation changes, such as fibrosis, 
tissue edema, or osteoradionecrosis [17,18]. Further-
more, even when lesions suggestive of recurrence are 
discovered in imaging studies, it is not feasible to do 
a biopsy of the tumor in these areas [16,17]. There-
fore, repeated imaging studies to follow tumor growth 
are the only reliable way to confirm tumor recurrence 
[15,16] before a PET scan is carried out.
PET is a functional imaging technique, which can 
provide information about the metabolic rate in le-
sions. Because the cancer cells of NPC have high glu-
cose utilization, an 18F-FDG PET scan can be applied 
to detect tumors, under the basis of a higher glycolytic 
rate of the viable cells. Previous studies have shown 
that PET scans are valuable in detecting locoregional 
recurrences of NPC with a high sensitivity and accept-
able specificity, especially when the clinical findings 
are uncertain or the morphological imaging results 
are controversial [7–10]. However, many false-positive 
results can occur due to other benign conditions, 
such as active inflammatory processes, osteoradio-
necrosis or other granulomatous lesions, which also 
have a high glucose metabolism [7,12,13,19]. False-
positive results are now the main problem of PET scans 
in the detection of recurrent NPC at the primary site 
in clinical practice [12,19].
In contrast, a false-negative PET result has rarely 
been reported. A negative PET scan is generally 
thought to confidently exclude a tumor. However, 
false-negative scans still may occur when the tumor 
is small (> 0.5 cm) or when the tumor itself has lower 
intracellular accumulation of 18F-FDG [7]. In the man-
agement of cancers, a false-negative result is more 
dangerous than a false-positive report. This is be-
cause there is no tumor in a false-negative situation, 
but an undiscovered recurrent tumor will grow more 
advanced without proper management and will fi-
nally lead to the patient’s death. Therefore, negative 
PET scans must be carefully interpreted.
Here, we describe a false-negative PET scan in a 
patient with NPC with a recurrent tumor in the left 
cavernous sinus, who presented with new onset of 
left 6th cranial nerve palsy only 1 year after irradia-
tion. Sixth cranial nerve palsy is one of the late com-
plications of irradiation, but usually occurs more than 
5 years after treatment [20,21]. Even after achieving 
complete tumor regression for many years, patients 
with recurrent disease may still present with cranial 
nerve palsy [21]. In the patients who present with 
recurrent cranial nerve palsy after receiving radio-
therapy, tumor recurrence is possible and investiga-
tions should be carried out unless the recurrence is 
excluded [21]. Therefore, in our case, despite the 
fact that MRI failed to reveal any significant lesion, a 
PET scan was performed, but this also showed no 
significant 18F-FDG uptake. Because a recurrent tumor 
was not confidently excluded, a second MRI scan was 
performed 3 months later. This MRI demonstrated a 
new abnormal lesion in the left cavernous sinus re-
gion, which was compatible with the patient’s clini-
cal symptoms. Despite the fact that pathological 
evidence was not available because of the difficulty 
of obtaining tissue from this region, recovery of left 
6th cranial nerve function and the resolution of the 
cavernous sinus lesion as shown by the following 
MRI 3 months after the second dose of irradiation 
implied that the cavernous sinus lesion was really a 
recurrent tumor [22,23]. From the treatment experi-
ence of this patient, it is possible that a PET scan 
may fail to detect a small recurrent tumor, which is 
Fig. 4 — Coronal view of T1-weighted magnetic resonance 
imaging with gadolinium enhancement, which was per-
formed 3 months after re-irradiation, shows that the recur-
rent tumor had disappeared.
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not shown by other imaging modalities. Although ini-
tial imaging studies may not be compatible with a 
patient’s clinical symptoms, close observation with a 
high index of suspicion for a tumor is very important. 
Regular and long-term follow-up with a series of im-
aging studies must be performed when indicated 
[15,24–26], especially for patients who have persist-
ent, even progressive, symptoms or signs that cannot 
be solely explained just as early or late complications 
of their previous treatments.
4. Conclusion
The clinical value of PET scans for diagnosis of recur-
rent NPC has been well-established. However, PET 
scans still have limitations. False-negative PET results 
must be carefully interpreted because they are more 
dangerous than false-positive results. Clinical pic-
tures are still important, especially for those patients 
who have discrepancies in the physical examinations 
and the image results. The image studies must be 
performed repeatedly to detect small recurrent tu-
mors early when the PET scans are negative in a high 
risk patient.
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